{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:11:02Z","timestamp":1764493862031},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"10_Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,15]]},"DOI":"10.2146\/ajhp150966","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T18:25:30Z","timestamp":1462386330000},"page":"s5-s13","source":"Crossref","is-referenced-by-count":10,"title":["Overview of direct oral anticoagulant therapy reversal"],"prefix":"10.1093","volume":"73","author":[{"given":"Michael P.","family":"Gulseth","sequence":"first","affiliation":[{"name":"Anticoagulation Services, Sanford University of South Dakota Medical Center, Sioux Falls, SD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041102204044500_b1-07300s5","unstructured":"Boehringer Ingelheim Pharmaceuticals. Pradaxa (dabigatran etexilate mesylate) prescribing information. http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf (accessed 2016 Jan 7)."},{"key":"key\n\t\t\t\t2019041102204044500_b2-07300s5","unstructured":"Bristol-Myers Squibb. Eliquis (apixaban) prescribing information. http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf (accessed 2015 Jul 30)."},{"key":"key\n\t\t\t\t2019041102204044500_b3-07300s5","unstructured":"Daiichi Sankyo. Savaysa (edoxaban) prescribing information. http:\/\/dsi.com\/prescribing-information-portlet\/getPIContent?productName=Savaysa&inline=true (accessed 2015 Jul 30)."},{"key":"key\n\t\t\t\t2019041102204044500_b4-07300s5","unstructured":"Janssen Pharmaceuticals. Xarelto (rivaroxaban) prescribing information. www.xareltohcp.com\/shared\/product\/xarelto\/prescribing-information.pdf (accessed 2015 Jul 30)."},{"key":"key\n\t\t\t\t2019041102204044500_b5-07300s5","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","article-title":"Overview of the new oral anticoagulants: opportunities and challenges","volume":"35","author":"Yeh","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t2019041102204044500_b6-07300s5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t2019041102204044500_b7-07300s5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041102204044500_b8-07300s5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014 an oral, direct factor Xa inhibitor\u2014 after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041102204044500_b9-07300s5","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t2019041102204044500_b10-07300s5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041102204044500_b11-07300s5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t2019041102204044500_b12-07300s5","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1124\/dmd.112.046888","article-title":"Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans","volume":"40","author":"Bathala","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t2019041102204044500_b13-07300s5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041102204044500_b14-07300s5","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.2146\/ajhp130042","article-title":"Developing a management plan for oral anticoagulant reversal","volume":"70","author":"Dager","year":"2013","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019041102204044500_b15-07300s5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/clc.22037","article-title":"Emergency management of bleeding associated with old and new oral anticoagulants","volume":"35","author":"Peacock","year":"2012","journal-title":"Clin Cardiol"},{"key":"key\n\t\t\t\t2019041102204044500_b16-07300s5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102204044500_b17-07300s5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102204044500_b18-07300s5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102204044500_b19-07300s5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","article-title":"Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial","volume":"125","author":"Hohnloser","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041102204044500_b20-07300s5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102204044500_b21-07300s5","first-page":"123","article-title":"Anticoagulation reversal","volume-title":"Anticoagulation therapy: a point-of-care guide","author":"Dougherty","year":"2011"},{"key":"key\n\t\t\t\t2019041102204044500_b22-07300s5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jemermed.2012.11.032","article-title":"Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians","volume":"45","author":"Brem","year":"2013","journal-title":"J Emerg Med"},{"key":"key\n\t\t\t\t2019041102204044500_b23-07300s5","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041102204044500_b24-07300s5","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1111\/jth.12949","article-title":"Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal","volume":"13","author":"Dzik","year":"2015","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t2019041102204044500_b25-07300s5","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.2146\/ajhp130243","article-title":"Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations","volume":"70","author":"Nutescu","year":"2013","journal-title":"Am J Health-Syst Pharm"},{"issue":"suppl 2","key":"key\n\t\t\t\t2019041102204044500_b26-07300s5","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2146\/ajhp150960","article-title":"Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants","volume":"73","author":"Dager","year":"2016","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019041102204044500_b27-07300s5","doi-asserted-by":"crossref","first-page":"ITC2","DOI":"10.7326\/0003-4819-159-3-201308060-01002","article-title":"Acute gastrointestinal bleeding","volume":"159","author":"Prasad Kerlin","year":"2013","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041102204044500_b28-07300s5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.amj.2014.08.008","article-title":"Coagulation: part 2","volume":"33","author":"Dries","year":"2014","journal-title":"Air Med J"},{"key":"key\n\t\t\t\t2019041102204044500_b29-07300s5","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2146\/ajhp110725","article-title":"Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient","volume":"69","author":"Miyares","year":"2012","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019041102204044500_b30-07300s5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jemermed.2013.03.016","article-title":"Managing bleeding in anticoagulated patients in the emergency care setting","volume":"45","author":"Pollack","year":"2013","journal-title":"J Emerg Med"},{"key":"key\n\t\t\t\t2019041102204044500_b31-07300s5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jen.2014.04.016","article-title":"Use of four-factor prothrombin complex concentrate in the emergency department: a review","volume":"41","author":"Willis","year":"2015","journal-title":"J Emerg Nurs"},{"key":"key\n\t\t\t\t2019041102204044500_b32-07300s5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/1742-6723.12156","article-title":"New oral anticoagulants: an emergency department overview","volume":"25","author":"Wood","year":"2013","journal-title":"Emerg Med Australas"},{"key":"key\n\t\t\t\t2019041102204044500_b33-07300s5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"key\n\t\t\t\t2019041102204044500_b34-07300s5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/21548331.2015.1103190","article-title":"Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"43","author":"Sarma","year":"2015","journal-title":"Hosp Pract"},{"key":"key\n\t\t\t\t2019041102204044500_b35-07300s5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/17474086.2016.1112733","article-title":"How to effectively manage the event of bleeding complications when using anticoagulants","volume":"9","author":"Sartori","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"key\n\t\t\t\t2019041102204044500_b36-07300s5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","article-title":"Acute management of bleeding in patients on novel oral anticoagulants","volume":"34","author":"Siegal","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041102204044500_b37-07300s5","first-page":"CD001886","article-title":"Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion","volume":"3","author":"Henry","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019041102204044500_b38-07300s5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041102204044500_b39-07300s5","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"Van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"issue":"suppl 2","key":"key\n\t\t\t\t2019041102204044500_b40-07300s5","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2146\/ajhp150959","article-title":"Reversal agents for use with direct and indirect anticoagulants","volume":"73","author":"Smythe","year":"2016","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019041102204044500_b41-07300s5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041102204044500_b42-07300s5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-3148.2009.00913.x","article-title":"Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events","volume":"19","author":"Hsia","year":"2009","journal-title":"Transfus Med"},{"key":"key\n\t\t\t\t2019041102204044500_b43-07300s5","unstructured":"Boehringer Ingelheim. Praxbind prescribing information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/761025lbl.pdf (accessed 2015 Oct 22)."},{"key":"key\n\t\t\t\t2019041102204044500_b44-07300s5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH14-11-0982","article-title":"Reversal of anticoagulants: an overview of current developments","volume":"113","author":"Greinacher","year":"2015","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t2019041102204044500_b45-07300s5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019041102204044500_b46-07300s5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102204044500_b47-07300s5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t2019041102204044500_b48-07300s5","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102204044500_b49-07300s5","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102204044500_b50-07300s5","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/10_Supplement_2\/s5\/28333884\/ajhp0s5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T08:55:20Z","timestamp":1567846520000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/10_Supplement_2\/s5\/5101533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,15]]},"references-count":50,"journal-issue":{"issue":"10_Supplement_2","published-print":{"date-parts":[[2016,5,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp150966","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,5,15]]},"published":{"date-parts":[[2016,5,15]]}}}